The new facility is dedicated to the comprehensive diagnosis, treatment, and rehabilitation of balance and vertigo disorders, ...

The first-in-human trial is taking place at Na Homolce hospital in Prague, Czech Republic, and will treat up to 50 patients.

Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré ...

Researchers have discovered that with the dual inhibition of C5 and factor D, patients with paroxysmal nocturnal ...

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today ...

Panelists discuss how Brandi first noticed symptoms leading to her paroxysmal nocturnal hemoglobinuria (PNH) diagnosis, highlighting the challenges of the initial diagnostic process, and explore the ...

A noteworthy case study. What's next for a premenopausal 40-year-old woman in Syria with recurrent hormone receptor-positive ...

Olav Bergheim has stepped down from his roles as CEO and chairperson but will continue to serve as an adviser for a year.

If you've been on your share of amusement park rides, you probably know what vertigo is like — the feeling that the world is spinning around you. But if you feel dizzy and didn't just step off a ...

CardioFocus announced that investigators completed the first series of treatments in a study of its OptiShot pulsed-field ...

In the U.S., atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the ...